Publication Bias in Reports of Animal Stroke Studies Leads to Major Overstatement of Efficacy

Publication bias confounds attempts to use systematic reviews to assess the efficacy of various interventions tested in experiments modelling acute ischaemic stroke, leading to a 30% overstatement of efficacy of interventions tested in animals

Systematic review and meta-analysis of the efficacy of interleukin-1 receptor antagonist in animal models of stroke: an update

Interleukin-1 receptor antagonist (IL-1 RA) is an anti-inflammatory protein used clinically to treat rheumatoid arthritis and is considered a promising candidate therapy for stroke. Here, we sought to update the existing systematic review and meta-analysis of IL-1 RA in models of ischaemic stroke, published in 2009, to assess efficacy, the range of circumstances in which efficacy has been tested and whether the data appear to be confounded due to reported study quality and publication bias. We included 25 sources of data, 11 of which were additional to the original review. Overall, IL-1 RA reduced infarct volume by 36.2 % (95 % confidence interval 31.6–40.7, n = 76 comparisons from 1283 animals). Assessments for publication bias suggest 30 theoretically missing studies which reduce efficacy to 21.9 % (17.3–26.4). Efficacy was higher where IL-1 RA was administered directly into the ventricles rather than peripherally, and studies not reporting allocation concealment during the induction of ischaemia reported larger treatment effects. The preclinical data supporting IL-1 RA as a candidate therapy for ischaemic stroke have improved. The reporting of measures to reduce the risk of bias has improved substantially in this update, and studies now include the use of animals with relevant co-morbidities. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s12975-016-0489-z) contains supplementary material, which is available to authorized users

The Efficacy of Trastuzumab in Animal Models of Breast Cancer:A Systematic Review and Meta-Analysis

BACKGROUND:Breast cancer is the most frequent cancers and is the second leading cause of cancer death among women. Trastuzumab is an effective treatment, the first monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2). To inform the development of other effective treatments we report summary estimates of efficacy of trastuzumab on survival and tumour volume in animal models of breast cancer. METHODS:We searched PubMed and EMBASE systematically to identify publications testing trastuzumab in animal models of breast cancer. Data describing tumour volume, median survival and animal features were extracted and we assessed quality using a 12-item checklist. We analysed the impact of study design and quality and evidence for publication bias. RESULTS:We included data from 83 studies reporting 169 experiments using 2076 mice. Trastuzumab treatment caused a substantial reduction in tumour growth, with tumours in treated animals growing to 32.6% of the volume of tumours in control animals (95%CI 27.8%-38.2%). Median survival was prolonged by a factor of 1.45 (1.30-1.62). Many study design and quality features accounted for between-study heterogeneity and we found evidence suggesting publication bias. CONCLUSION:We have found trastuzumab to be effective in animal breast cancer models across a range of experimental circumstances. However the presence of publication bias and a low prevalence of measures to reduce bias provide a focus for future improvements in preclinical breast cancer research

DuVal 2012 - fidelity and male siring rank

Data used to investigate whether females are more likely to return to mate with highly successful males. Data are 111 observations of nesting by 68 females that mated with males alive in the following breeding season, with subsets specified for some subsequent analyses. See README file for detailed description of table fields

Data from: Female mate fidelity in a lek mating system and its implications for the evolution of cooperative lekking behavior

The extent and importance of female mate fidelity in polygynous mating systems are poorly known. Fidelity may contribute to high variance in male reproductive success when it favors attractive mates or may stabilize social interactions if females are faithful to mating sites rather than males. Using 12 years of data on genetic mate choice in the cooperatively lekking lance-tailed manakin (Chiroxiphia lanceolata), I investigated the frequency of fidelity within and between years, whether females were faithful to individual males or to mating sites across years, and whether fidelity favored attractive males. Mate fidelity occurred in 41.7% of 120 between-year comparisons and was observed for 41.1% of 73 individual females that had the opportunity to mate faithfully. Females were not more likely to mate at prior mating sites when previous mates were replaced. Faithful females mated with the same male in up to four consecutive years but were not disproportionately faithful to attractive partners. Mating history influences current mate choice, and fidelity in this lekking system apparently represents active mate choice by females but little consensus in mate choices among faithful females. This study underscores the prevalence of mate fidelity in polygynous mating systems and emphasizes the need to consider the larger context of lifetime reproductive behavior when interpreting patterns of female choice

DuVal 2012 - Fidelity and annual male success

Data used to assess the proportionate influence of mate fidelity for males' annual reproductive success. Data are 62 observations on 35 males that sired any chicks through fidelity in 2000-2011. See README file for detailed description of table fields

DuVal 2012 - Fidelity and total male success

Data used to assess whether successful males achieve disproportionate levels of success through mate fidelity. Data are 110 individual males siring any chicks in 2000-2011. See README file for detailed description of table fields